Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...

Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do ...

Omvoh (mirikizumab-mrkz) for moderately to severely active Crohn’s disease in adults. Omvoh is now approved in the U.S. for ...

Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide ...

The race is on for new drugs that suppress appetite, improve glucose regulation and can replace injections. But do they ...

Eli Lilly (LLY) expects that its experimental weight loss pill will get approved as soon as early next year, CEO David Ricks said in an ...

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which dominate the weight loss drug market.

Ozempic, Wegovy or Mounjaro? The battle of the weight-loss injections - As drugs emerge as vital to the Government’s ...

A non-opioid painkiller from Vertex Pharmaceuticals could become a blockbuster, but questions remain on whether it will prove ...

Given that more than 40% of Indian adults are struggling with obesity and diabetes, affordable weight-loss drugs are expected ...

Weight-loss medication like Semaglutide and Tirzepatide has seen a rise in demand, causing a boom in sales. This exploding ...